Skip to content
BioalmanacPeptide reference
Account
Menu

Stack

BPC-157, TB-500 and GHK-Cu

The repair pairing with a copper peptide added for connective tissue. Three preclinical compounds, and the copper is the one with an actual ceiling.

The base is the repair pairing everyone runs. BPC-157 daily, TB-500 weekly, on the reasoning that recovery needs new blood supply and cells arriving to use it.

GHK-Cu comes in for the connective tissue side, on human topical work associating it with collagen synthesis and remodelling. That evidence is genuinely the strongest of the three. It is also evidence about skin, applied to skin.

Injecting it is a different question. The studies usually cited for GHK-Cu are not studies of injection. That is a specific gap, not a general shortage of data.

One thing separates this from most three-compound stacks. Copper is an essential trace element with a real upper limit, so the third compound is not just another unknown. It delivers something the body already regulates.

The schedule

Commonly run, not recommended

10 weeks. Doses are what sources describe rather than what we advise — where a source gave a range we show the range instead of choosing a number inside it.

Each compound in BPC-157, TB-500 and GHK-Cu, with its dose and schedule.
CompoundDoseHow oftenWeeks
BPC-157PreclinicalDaily throughout. Associated with new blood supply to injured tissue.200 mcg–500 mcg2× dailyOften split morning and evening.1–10
TB-500PreclinicalWeekly. Associated with cell migration into damaged tissue.2 mg–5 mgWeekly · MonUsually described as a higher loading dose for the first weeks, dropped afterwards.1–6
GHK-CuPreclinicalFor the connective tissue side. The copper-carrying half, and the one with a ceiling.1000 mcg–2000 mcgOnce dailyKept in its own vial. Copper is reactive and the compatibility of these mixtures is not characterised.1–10

Start this stack

Things worth knowing

  • Copper has an upper limit and GHK-Cu delivers copper. Add AHK-Cu, a copper-containing blend or a copper supplement and you are stacking sources of the same thing. It is one of the few genuine interactions in this category.
  • GHK-Cu's human evidence is topical. Injecting it is not supported by the studies usually cited for it.
  • Injection site reactions are the most commonly reported effect of GHK-Cu. On a daily subcutaneous schedule, rotation stops being optional.
  • Three preclinical compounds at once means nothing can be pinned on any of them, and an injury that improves would probably have improved anyway.

Related

Another stackBPC-157 and GHK-CuThe two components of GLOW without the TB-500, run separately so each can be dosed on its own schedule and route.Another stackBPC-157 and TB-500The most commonly run repair pairing. Two compounds on different schedules, on the reasoning that one builds blood supply and the other moves cells into the gap.

Questions

Can all three go in one syringe?
Copper peptides are generally kept separate. Copper is reactive and nobody has characterised these mixtures. The simpler reason is that mixing takes away your ability to stop one of them, and the three schedules differ anyway.
Is the copper a problem?
It is the thing to watch. Unlike the other two compounds, copper has a real upper limit, so the risk adds up across every source: a second copper peptide, a blend containing one, a supplement.
How long before anything is noticeable?
Tissue repair sets the floor no matter what you are taking. Connective tissue remodelling runs to months. Anything you notice in a fortnight is more likely reduced inflammation or ordinary healing than anything the stack did.

This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on Bioalmanac is medical advice.